Featured Article

Apremilast (brand name Otezla) is an oral therapy for the treatment of certain inflammatory conditions including psoriatic arthritis, psoriasis, and ankylosing spondylitis. It was approved by the U.S. Food and Drug Administration (FDA) in 2014 for the treatment of these conditions. Apremilast is an oral, non-steroidal anti-inflammatory drug (NSAID), and it works by blocking the activity of an enzyme involved in inflammation, known as phosphodiesterase (PDE).

Apremilast is a safe and effective treatment for inflammatory conditions, and has been shown to bring about a number of positive benefits. For psoriasis, it has been found to reduce redness, itching, and scaling when taken in combination with other therapies. For ankylosing spondylitis, it has been found to provide significant relief of pain, stiffness, and fatigue.

Apremilast has also been beneficial in reducing the signs and symptoms of psoriatic arthritis, including pain, tenderness, swelling, and joint stiffness. It is considered an advantageous therapy as it is easy to take and has been demonstrated to reduce the need for NSAIDs or biologic therapies.

Apremilast has been found to cause fewer gastrointestinal side effects when compared to other medications used to treat inflammatory conditions. In addition, it is associated with a lower risk of serious side effects than other therapy regimens.

Lastly, patients taking apremilast have reported improved quality of life due to the relief of pain and other symptoms associated with their condition.

Overall, apremilast is a safe and effective oral therapy for a number of inflammatory conditions, and offers a number of positive benefits for those affected. If you have been diagnosed with any of these conditions, it may be worth discussing the potential benefits of apremilast with your doctor.